Nav: Home

Gonorrhoea strains across Europe becoming more susceptible to main treatment options

September 13, 2017

According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010. However, resistance to one antibiotic agent which is part of the suggested dual therapy of gonorrhoea remains high and threatens the effectiveness of this regimen.

Every year, countries of the European Union and European Economic Area (EU/EEA) participate in Euro-GASP to test susceptibility of Neisseria gonorrhoeae to the antibiotics commonly used for gonorrhoea treatment. In 2015, 24 EU/EEA countries collected and tested more than 2 000 gonococcal isolates that showed stable proportions of resistance against the antimicrobials cefixime, ciprofloxacin and azithromycin compared to 2014 and only one isolate resistant to ceftriaxone.

Cefixime resistance decreased slightly to 1.7% in 2015 in comparison to the year before (2%). Ciprofloxacin resistance, although still very high, has decreased from 53% in 2013 to 49% in 2015 and the level of azithromycin resistance went down from 8% in 2014 (169 out of 2 147 isolates) to 7% in 2015. However, five isolates displayed high-level resistance to azithromycin, compared with only one in 2014. Only one isolate displayed resistance to ceftriaxone in 2015, compared to five in 2014 and seven in 2013.

The continuing increase in cephalosporin susceptibility is good news considering that these are among the last remaining options for treatment of gonorrhea infection. Despite this, the level of azithromycin resistance and the rise in the number of isolates with high-level resistance to azithromycin are of major concern and threaten the effectiveness of the dual antimicrobial treatment regimen.

The ECDC report Gonococcal antimicrobial susceptibility surveillance in Europe 2015 shows that information about which antimicrobials were used to treat gonorrhoea infection were available for 36.5% of patients (779 of 2134 isolates). 58% of these received the recommended treatment of ceftriaxone and azithromycin, although the dosages were not available. Overall, 87% were administered ceftriaxone with or without azithromycin, so the use of the recommended and more appropriate ceftriaxone may have contributed to this increase in cephalosporin susceptibility. More heterosexual males received the recommended treatment (67%) than females (57%) and men who have sex with men (52%).

Euro-GASP monitors emerging resistance trends A

s the control of gonorrhoea depends on effective antimicrobial treatment, even a small increase in drug resistance has a relevant impact due to the risk of treatment failure.

Since the European treatment guidelines for gonorrhoea recommend use of two antimicrobials (ceftriaxone or cefixime in combination with azithromycin), the surveillance of antimicrobial susceptibility of these agents - which is currently undertaken by ECDC's Euro-GASP - is vital to guide clinical services to ensure that patients are successfully treated and the risk of complications are avoided.

With more than 66 000 reported cases in 2014, and many more infections occurring but not reported, gonorrhoea is the second most frequently recorded sexually transmitted infection in Europe after chlamydia.

ECDC launched a regional response plan to control multidrug-resistant gonorrhoea to minimise the threat of drug-resistant gonorrhoea in Europe. This plan argues that countries need to ensure they have the minimum capacity for culture and susceptibility testing. They must also have strategies for rapid identification and reporting of failures to treatment with currently recommended antimicrobials.

At the same time, antimicrobial resistance surveillance and awareness of this problem should be stepped up so that measures can be taken to ensure that options for successful treatment of gonorrhoea remain available in the EU.
-end-


European Centre for Disease Prevention and Control (ECDC)

Related Azithromycin Articles:

Common antibiotic azithromycin not linked to increased risk of abnormal heartbeat
The commonly used antibiotic azithromycin is not linked to an increased risk of ventricular arrhythmia, an often life-threatening rapid, irregular heartbeat, according to a large study published in CMAJ.
Encouraging decrease in certain antibiotic resistance levels of gonococci across Europe
In 2014, the susceptibility of gonococci to two of the recommended antibiotics for gonorrhoea treatment has shown signs of improvement, according to results from the European Gonococcal Antimicrobial Surveillance Programme.
Europe sees constant increase in gonorrhoea infections
Since 2008, the overall rate of reported gonorrhea infections has more than doubled across Europe, going up from 8 per 100,000 population to 20 cases per 100,000 persons in 2014.
Common macrolide antibiotics show no increased risk of serious heart arrhythmia or death
The US Food and Drug Administration (FDA) warning about the risk of serious heart rhythm disturbances and death with macrolide antibiotics use may be overstated, according to a large study published in Canadian Medical Association Journal.
Study found adding azithromycin to standard antibiotic reduced infections in C-sections
In a study to be presented on Feb. 4 in an oral concurrent session at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in Atlanta, researchers present findings from a study that looked at the benefit of using adjunctive azithromycin to prevent infections after cesarean delivery.
Antibiotic use in early life disrupt normal gut microbiota development
The use of antibiotics in early childhood interferes with normal development of the intestinal microbiota, shows research conducted at the University of Helsinki.
Early use of antibiotic for recurrent, severe lower respiratory illness in children
Among young children with histories of recurrent severe lower respiratory tract illness (LRTI), the use of azithromycin early during an apparent RTI compared with placebo significantly reduced the risk of experiencing progression to severe LRTI, according to a study in the Nov.
For kids prone to wheezing with respiratory infections, early antibiotics help
In children whose colds tend to progress and lead to severe wheezing and difficulty breathing -- such that they are given oral corticosteroids as rescue therapy -- research led by Washington University School of Medicine in St.
Common antibiotics increase risk of cardiac arrhythmias, cardiac death
Macrolides -- a group of commonly used antibiotics for bacterial infections like pneumonia, bronchitis, and some sexually transmitted diseases -- are associated with a small but statistically significant increased risk of sudden cardiac death, according to a meta-analysis of 33 studies involving more than 20 million patients published today in the Journal of the American College of Cardiology.
Pregnancy antibiotics no cause for concern
The four out of ten women who use antibiotics during pregnancy can breathe easy, as a comprehensive new study shows that the two most often prescribed drugs have no adverse outcome on the child's physical development.

Related Azithromycin Reading:

Medical Guide: AZITHROMYCIN Tablet: An Antibiotic Prescription Medicine Used To Treat Certain Infections
by James Lee Anderson (Author)

“Although, your health condition may impact your everyday life, do not let it define who you are.” Azithromycin tablets are a macrolide antibiotic prescription medicine used in adults 18 years or older to treat certain infections caused by certain germs called bacteria. These bacterial infections include: acute worsening of chronic bronchitis, acute sinus infection, community-acquired pneumonia, infected throat or tonsils, skin infections, infections of the urethra or cervix and genital ulcers in men. Azithromycin tablets are also used in children to treat: ear infections,... View Details


Taste Masked Azithromycin Dispersible Tablets for Pediatrics: Pharmaceutical Technology
by Birjusinh J. Parmar (Author), Pallav V. Simariya (Author)

Oral administration is the most popular route due to ease of manufacturing, pain avoidance, accurate dosing, stability and ease of administration. However, pediatric patients find it difficult to swallow solid dosage forms like tablets and do not take their medication as prescribed. This results in high incidence of patient non- compliance and ineffective therapy. Azithromycin is a very bitter drug and it is best suited drug for the treatment of Pneumonia. In market there are lots of formulations of Azithromycin is available but it’s bitter taste leads to poor patient compliance. Moreover,... View Details


Azithromycin in the Treatment of Acute Exacerbations of Chronic Bronchitis in Adults (Clinical Review)
by Andy Hoepelman (Author)

View Details


Azithromycin in the Treatment of Skin and Soft-tissue Infections (Clinical Review)
by Adolfo Fernandez-Obregon (Editor)

View Details


Azithromycin in the Treatment of Community-Acquired Pneumonia in Adults (Clinical Review)
by Hartmut Lode (Author)

View Details


A Cure for Asthma?: What Your Doctor Isn't Telling You--and Why
by David L. Hahn MD MS (Author)

This book challenges conventional wisdom about the causes and treatments of asthma. Could hard-to-treat asthma be triggered by a persistent infection? Dr. David Hahn presents the scientific evidence and compelling case histories that led him to his surprising conclusion. He describes the treatment protocol he has used successfully. Find out if your asthma might be cured once and for all instead of managed. View Details


Azithromycin: Webster's Timeline History, 1980 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Azithromycin," including when used in literature (e.g. all authors that might have Azithromycin in their name). As such, this book represents the largest compilation of timeline events associated with Azithromycin when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative... View Details


Bronchiolitis Obliterans Syndrome After Lung Transplantation: Azithromycin Therapy and Beyond (Acta Biomediaca Lovaniensia)
by Bart Vanaudenaerde (Author)

View Details


Pharmacokinetics and Tissue Targeting of Azithromycin (Clinical Review)
by Guy Amsden (Author)

View Details


Cost Effectiveness of Azithromycin Versus Cefuroxime, with/without Erythromycin, in Hospitalized Patients with Community Acquired Pneumonia
by Larry D. Gudgel (Author)

View Details

Best Science Podcasts 2017

We have hand picked the best science podcasts for 2017. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Simple Solutions
Sometimes, the best solutions to complex problems are simple. But simple doesn't always mean easy. This hour, TED speakers describe the innovation and hard work that goes into achieving simplicity. Guests include designer Mileha Soneji, chef Sam Kass, sleep researcher Wendy Troxel, public health advocate Myriam Sidibe, and engineer Amos Winter.
Now Playing: Science for the People

#448 Pavlov (Rebroadcast)
This week, we're learning about the life and work of a groundbreaking physiologist whose work on learning and instinct is familiar worldwide, and almost universally misunderstood. We'll spend the hour with Daniel Todes, Ph.D, Professor of History of Medicine at The Johns Hopkins University, discussing his book "Ivan Pavlov: A Russian Life in Science."